As the most frequently prescribed anti-diabetic drug, metformin has a demonstrated record of safety, and therefore the identification of different subtypes of liver cancer patient may provide an expanded range of options for patients with low DOCK1 expression. This evidence concerns the gene DOCK1 and liver cancer.